| </=,<= | |
| >/=,>= | |
| ≤,<= | |
| ≥,>= | |
| 2nd generation,2nd-generation | |
| 5etc times/day,5x/day | |
| Absorption t1/2,t1/2\a | |
| Adverse drug reaction,ADR | |
| Anti-proliferative ,Antiproliferative | |
| Anti-rejection ,Antirejection | |
| Area under curve,AUC | |
| Average concentration,Cavg | |
| Body-weight,Body weight | |
| Broad spectrum,Broad-spectrum | |
| Centi,c | |
| Clearance,Cl | |
| Compared to,cf | |
| Complete response,CR | |
| Composition-of-matter,Composition of matter | |
| Day,day | |
| Days,days | |
| Deci,d | |
| Decilitre,10ml | |
| Dose-limiting toxicities,DLTs | |
| Dose-limiting toxicity,DLT | |
| double blind,double-blind | |
| double masked,double-masked | |
| Drug concentration producing 50% maximum response,EC50 | |
| Drug concentration that reduces response to another drug by 50%,IC50 | |
| early stage,early-stage | |
| Effective dose in 50% patients,ED50 | |
| Elimination t1/2,t1/2\b | |
| Every 10 days,q 10 days | |
| Every 3 weeks,q 3wk | |
| Extended Access,extended-access | |
| Fast track,Fast-track | |
| Fat rich,Fat-rich | |
| For 3 weeks,x3wk | |
| For 5 days,x5 days | |
| Forced Expiratory Volume in 1 sec,FEV1 | |
| Four times a day,qid | |
| Graft versus host,Graft-versus-host | |
| Gram,g | |
| Half-life,t1/2 | |
| Hour,hr | |
| Hours,hr | |
| International units,IU | |
| Intramuscular,im | |
| Intravenous,iv | |
| Kaplan–Meier curves,KM curves | |
| Kilo,k | |
| Kilogram,kg | |
| Litre/dm3,l | |
| Maximum tolerated dose,MTD | |
| Micro,\u | |
| Microgram,\ug | |
| Milli,m | |
| Milligram,mg | |
| Millilitre/cm3,ml | |
| Minute,min | |
| Minutes,min | |
| Moderate to severe,Moderate-to-severe | |
| Molar (NB,Mlar is the same as moles/litre or moles/dm3),M | |
| Mole,mol | |
| Month,mth | |
| Months,mth | |
| Nano,n | |
| Nanogram,ng | |
| Netherlands,The Netherlands | |
| Non Randomized,non-randomized | |
| Once daily,once-daily | |
| Once weekly,1x/wk | |
| Open label,open-label | |
| Oral,po | |
| Orally,po | |
| Overall survival,OS | |
| Parallel Assignment,parallel-assignment | |
| Peak plasma conc.,Cmax | |
| per day,/day | |
| Pico,p | |
| Picogram,pg | |
| Placebo-controlled,placebo-controlled | |
| Progression-free survival,PFS | |
| Proof of concept,proof-of-concept | |
| pts,patients | |
| Quarter,qtr | |
| Randomized,randomized | |
| Second half of 2017,2nd half of 2017 | |
| Second,s | |
| Seconds,s | |
| Side effects,side-effects | |
| Single Group,single-group | |
| ß,beta | |
| Stable disease,SD | |
| Subcutaneous,sc | |
| TEAEs,treatment-emergent adverse events | |
| Three times a day,tid | |
| Three times a week,3x/wk | |
| Time to disease,Time-to-disease | |
| Time to disease progression,Time-to-disease progression | |
| Time to from admin. to Cmax,Tmax | |
| Twice daily,bid | |
| Twice per week,2x/wk | |
| United Kingdom,The UK | |
| United States,The US | |
| Units,U | |
| Versus,vs | |
| Volume of distribution,Vd | |
| Week,wk | |
| Weeks,wk | |
| Well-tolerated,Well tolerated | |
| Year,yr | |
| Years,yr | |
| α,alpha | |
| γ,gamma | |
| δ,delta | |
| σ,sigma | |
| participants,subjects | |
| The purpose of this study is, | |
| The purpose of this study was, | |
| The purpose of the study is, | |
| The main aim of the study is, | |
| The objective of the trial is, | |
| The objective of the study is, | |
| to find out,to evaluate | |
| to demonstrate,to demonstrate | |
| to see,to assess | |
| to compare,to compare | |
| to evaluate,to evaluate | |
| to determine,to determine | |
| to investigate,to investigate | |
| study of, to evaluate | |
| phase 1,Phase I | |
| phase 2,Phase II | |
| phase 3,Phase III | |
| phase 1/2,Phase I/II | |
| phase 2/3,Phase II/III | |
| phase i,Phase I | |
| phase ii,Phase II | |
| phase iii,Phase III | |
| one,1 | |
| two,2 | |
| three,3 | |
| four,4 | |
| five,5 | |
| six,6 | |
| seven,7 | |
| eight,8 | |
| nine,9 | |
| eleven,11 | |
| |,/ | |
| Placebo comparator,Placebo-controlled | |
| Placebo controlled,Placebo-controlled | |
| placebo control,Placebo-controlled | |
| active comparator,active-controlled | |
| open label,open-label | |
| 4-week,4 wk | |
| 3-Week,3 wk | |
| British Approved Name,BAN | |
| International Nonproprietary Name,INN | |
| US Approved Name,USAN | |
| Acute myelogenous leukaemia,AML | |
| Acquired immune deficiency syndrome,AIDS | |
| Blood pressure,BP | |
| Chronic myelogenous leukaemia,CML | |
| Chronic Obstructive Pulmonary Disease,COPD | |
| Complete response,CR | |
| Deep vein thrombosis,DVT | |
| Forced Expiratory Volume in 1 sec,FEV1 | |
| Graft Versus Host disease,GvHD | |
| Heart rate,HR | |
| Hepatitis B/C virus,HBV/HCV | |
| Herpes simplex virus,HSV | |
| Highly active antiretroviral therapy,HAART | |
| Human immunodeficiency virus,HIV | |
| Inflammatory bowel disease,IBD | |
| Irritable bowel syndrome,IBS | |
| Multiple sclerosis,MS | |
| Myocardial infarction,MI | |
| Non-steroidal anti-inflammatory drug,NSAID | |
| Osteoarthritis,OA | |
| Partial response,PR | |
| Rheumatoid arthritis,RA | |
| Severe combined immunodeficiency,SCID | |
| Simian immunodeficiency virus,SIV | |
| Stable disease,SD | |
| Systemic lupus erythramatosus,SLE | |
| Biological Licence Application,BLA | |
| Co-operative research and development agreement,CRADA | |
| European Medicine Evaluation Agency,EMEA | |
| European Union's Committee for Proprietary Medicinal Products,CPMP | |
| Food and Drug Administration,FDA | |
| Investigational New Drug,IND | |
| Intellectual Property,IP | |
| Marketing Authorization Approval,MAA | |
| Medicine Control Agency,MCA | |
| New Drug Application,NDA | |
| Prescription Drug User Fee Act,PDUFA | |
| tumor,tumour | |
| tumors,tumours | |
| leukemia,leukaemia | |
| hematological,haematological | |
| alzheimer's disease,Alzheimer's disease | |
| egfr,EGFR | |
| EGFR,EGFR | |
| gilead,GILEAD |